A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies

Amer M Zeidan,Rachel J Cook, Rodolfo Bordoni,James R Berenson,William J Edenfield,Sanjay Mohan,Gongfu Zhou,Ekaterine Asatiani,Nithya Srinivas,Michael R Savona

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 2|浏览1

暂无评分

摘要

•JAK1 mediates inflammatory cytokines in hematologic malignancies.•We tested JAK1 inhibitors (INCB052793 or itacitinib) in a phase 1/2 study.•There were no unexpected toxicities from JAK1 inhibitor therapy.•JAK1 inhibition did not provide therapeutic benefit in patients.

查看译文

关键词

AML,JAK/STAT,Multiple myeloma,Myelodysplastic syndrome,Relapsed/refractory

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要